Can patients stop Anti-Rejection drugs sooner after transplant?
NCT ID NCT07302776
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether patients can safely stop the drug tacrolimus earlier than usual after a stem cell transplant. Tacrolimus is given to prevent graft-versus-host disease (GVHD), but newer methods have lowered GVHD risk. The trial will enroll 50 people with blood cancers and see if tapering off tacrolimus by day 88 is safe and does not cause severe GVHD by day 180.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tacrolimus
- What this could lead to
- If successful, this could show that stopping immunosuppression earlier after transplant is safe, potentially reducing side effects and improving recovery.
- What could go wrong
- This is a small, early-phase trial. Early tapering may increase the risk of graft-versus-host disease, which can be serious. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford University
Palo Alto, California, 94304, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Dual-Action pill tame bone marrow tumors?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can a new pill boost the power of an existing leukemia treatment?
- Can engineered immune cells outsmart Hard-to-Treat blood cancers?